BTIG analyst Ryan Zimmerman maintained a Buy rating on Stryker Corporation (NYSE:SYK) on Wednesday, setting a price target of $252, which is approximately 4.63% above the present share price of $240.85.
Zimmerman expects Stryker Corporation to post earnings per share (EPS) of $1.66 for the fourth quarter of 2020.
The current consensus among 14 TipRanks analysts is for a Moderate Buy rating of shares in Stryker, with an average price target of $243.17.
The analysts price targets range from a high of $272 to a low of $210.
In its latest earnings report, released on 09/30/2020, the company reported a quarterly revenue of $3.74 billion and a net profit of $861 million. The company's market cap is $88.81 billion.
According to TipRanks.com, BTIG analyst Ryan Zimmerman is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 19.2% and a 62.60% success rate.
Stryker Corp. engages in providing medical technology products and services. It operates through the following segments: Orthopaedics, MedSurg and Neurotechnology and Spine. The Orthopaedics segment provides reconstructive and trauma implant systems. The Medsurg segment deals with surgical equipment and navigation systems, endoscopy, patient handling, and reprocessed medical devices. The Neurotechnology and Spine segment pertains to spinal implants and neurovascular products. The company was founded by Homer H. Stryker in 1941 and is headquartered in Kalamazoo, MI.